pillbase.ru

Aimovig

Active substance: erenumab

erenumab

Centralised EU authorisationActive

Marketing holder: Novartis Europharm Limited

Verified 2026-10-09 · EMA

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
US 4
  • AIMOVIG
    INJECTION · ERENUMAB 70 mg/mL
    55513-841
    Amgen, Inc
  • AIMOVIG
    INJECTION · ERENUMAB 70 mg/mL
    55513-840
    Amgen, Inc
  • AIMOVIG
    INJECTION, SOLUTION · ERENUMAB 140 mg/mL
    55513-842
    Amgen, Inc
  • AIMOVIG
    INJECTION, SOLUTION · ERENUMAB 140 mg/mL
    55513-843
    Amgen, Inc
Import and control

Control by country

  • United Statesprescription only

    Source: openFDA NDC · record 01a1208c-783f-7a36-ae73-70ccb0d8d04a,01a12093-c3d7-72be-89f9-e73e6ff6b55f,01a12093-c4ed-78b1-90a8-8370c772c667,01a12096-450e-73da-b759-f6376eabeb50;count=4 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
EMEA/H/C/004447
Registration status
Active
ATC code
N02CD01
Sources
  • product · EMA · EMEA/H/C/004447 · Verified 2026-10-09
  • registration_status · EMA · EMEA/H/C/004447 · Verified 2026-10-09
  • ingredients.0 · EMA · EMEA/H/C/004447 · Verified 2026-10-09